

ChemComm

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: C. Hoarau, M. Muselli, C. Baudequin and L. Bischoff, *Chem. Commun.*, 2014, DOI: 10.1039/C4CC07917E.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ARTICLE

Cite this: DOI:
10.1039/x0xx00000xPd-Catalyzed Direct C-H Functionalization of
Imidazolones with Aryl- and Alkenyl Halides

Mickaël Muselli, Christine Baudequin, Christophe Hoarau,* Laurent Bischoff*

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Imidazolone is a fundamental naturally-occurring non-aromatic heterocycle intensively used in the synthesis of functional materials and pharmaceuticals. Notably, due to both small size and attractive fluorescent properties, imidazolones mostly 4-arylidene and/or 2-aryl(alkynyl)ated constitute the main cores of numerous fluorescent probes for biological studies. Among the most-representative members of this family are the green-fluorescent proteins (GFP), the Kaede protein and BODIPY-like Burgess fluorophore (figure 1).¹ As recent remarkable applications in drug-design, 2-aryl(alkyl)ated imidazolones have been specifically selected for the treatment of obesity-related disorders² and hypertension.³ They have also been found to display important biological activities⁴ as fatty acid synthase (FAS) inhibitors (figure 1).⁵





Figure 1 Imidazolone framework in functional materials and pharmaceuticals

Current synthetic methodologies towards highly functionalized imidazolones that allow challenging various substitutions at 2-position are mainly based upon a ring-closing condensation of α -amidoamides (scheme 1).⁶ This synthetic route is fraught


with the inherent difficulty in achieving highly electronically-different substrate scope so that notably, the 2-alkynylated imidazolones are mostly obtained via the 2-methyl imidazolones⁷ or oxazolone intermediates (scheme 1).⁸ Innovative synthetic methods enabling a late-stage functionalization of simple imidazolones are thus actively needed. By contrast with the structurally-related aromatic imidazole, conventional transition-metal cross-coupling reactions are however poorly appropriated due to the hard access to required 2-metallated or 2-halogenated imidazolones. To our knowledge, only the cross-coupling of 2-methylthio-imidazolone has been reported.⁹ In this context, the discovery of direct C-H functionalization of imidazolones methodologies^{10,11} is particularly useful (scheme 1). Herein, the first direct C-H arylation as well as alkenylation of 4,4'-dialkylimidazolones at 2-position with aryl- and alkenyl halides are reported under Pd⁽⁰⁾/Cu^(I) bis-catalysis.

• Previous works



Scheme 1 Previous and proposed access to 4-arylidene and 4,4'-dialkylimidazolones

Importantly, the activation of the imidazolone ring by prior N-oxidation is not required. This work represents a rare use of the direct C-H functionalization methodology applied to non-aromatic heterocycles.¹²


Table 1 Pd-catalyzed C-H arylation of *N*-benzyl-4,4'-cyclobutyl imidazolone **1a** with *p*-bromotoluene **2A** [a]

Entry	Ligand	Base	T (°C)	Yield [%] ^[b]
1	-	-	130	5
2	-	K ₂ CO ₃	130	63
3	-	Cs ₂ CO ₃	130	45
4	-	DBU	130	65
5	PPh ₃	DBU	130	92
6	PPh ₃	DBU ^[d]	110	92
7	PPh ₃	DBU	90	64
8	PPh ₃	DBU ^[d]	110	92 ^[c]

[a] Pd(OAc)₂ (5 mol%), CuI (1 equiv), Ligand (10 mol%), Base (2 equiv), **1a** (1 equiv), **2A** (1 mmol), DMF (0.35M), 12 h. [b] Yield based on isolated product after flash chromatography. [c] Scale up on 2 mmol of halide under optimized conditions. [d] 1 equiv of DBU used.

We started to explore the direct C-H coupling of 4,4'-cyclobutylimidazolone **1a** with *p*-bromotoluene **2A**. Indeed, any reaction occurred under the strictly Bellina's conditions under Pd⁽⁰⁾/Cu^(I) bis-catalysis without base and ligand assistance (Table 1, entry 1),¹³ the use of potassium carbonate base led to the desired product in 63% isolated yield (Table 1, entry 2). The reaction became fairly effective by using DBU base and the full conversion of imidazolone **1a** was finally reached using PPh₃ ligand (Table 1, entry 5).¹⁴ The reaction remained highly operative at a slightly lower 110 °C temperature, interestingly. We next investigated the generality of the optimized protocol using various arylhalides (Table 2). We found invariably that the electronic effect and the position of substituents on the aromatic unit of the halides slightly influenced the outcome of the reaction since various 2-arylated imidazolones **3aB-K** flanked with trifluoromethyl, cyano, fluoro and acetamido functions were isolated in good yields. Remarkably, the procedure remained successful with aryl iodides to produce imidazolones **3aA**, **3aC**, **3aG** and **3aK** in similar or better yields than those obtained using corresponding aryl bromides. Moreover, reaction of **1a** with *p*-iodobromobenzene **2K** proceeded highly selectively to afford the imidazolone **3aK** in good yield. The latter is useful to introduce further various substituents on the aromatic unit to design notably new precursors for biologically-active substances.

To extend the scope of this methodology, we focused on direct C-H alkenylation reaction with alkenylhalides. Interestingly, the direct C-H alkenylation of **1a** with 2-bromostyrene as its pure (*E*)-isomer was successfully achieved applying the above optimized C-H arylation protocol. However the 2-styrenylimidazolone **5aA** was isolated in poor 12% yield due to the low conversion of imidazolone **1a**.


Table 2 Pd-catalyzed direct C-H arylation of 4,4'-disubstituted imidazolones **1a-b** with aryl halides [a]

[a] Pd(OAc)₂ (5 mol%), CuI (1 equiv), PPh₃ (10 mol%), DBU (1 equiv), **1a-b** (1 equiv), HetAr-I or HetAr-Br (1 equiv), DMF (0.35 M), 110 °C, 12 h. [b] Yield based on isolated product after flash chromatography.


However, switching DMF solvent to toluene along with PPh₃ to P(*o*-tol)₃ ligand afforded the expected cycloalkylimidazolone **5aA** in 73% yield in line to our previous observations in the

oxazole series (Table 3).¹⁵ A similar reactivity was observed using freshly prepared Hermann-Beller palladacycle precluding that the direct C-H alkenylation may proceed with this precatalyst readily formed by reacting Pd(OAc)₂ with P(*o*-tol)₃ in toluene at 80°C.¹⁴ Interestingly, the C-H alkenylation of **1a** remained effective under steric effect when 1-iodostyrene coupling partner was used. Several bromoalkenes **4C-E** were also successfully coupled with **1a** to afford 2-alkenylated **5C-E** in fair yields (Table 3). The scope was finally completed by the innovative production of the imidazolone **5aF** bearing an acrylamide function at 2-position giving novel opportunities in functional-diversity (Table 3). Notably the acrylamide may provide access to complex aminoalkyles through full or partial reduction of the nitrile in combination with prior Michael-type addition reaction to the acrylamide system.

Table 3 Pd-catalyzed direct C-H alkenylation of 4,4'-disubstituted imidazolone **1a** with alkenylbromides^[a]



[a] Pd(OAc)₂ (5 mol%), CuI (1 equiv), P(*o*-tol)₃ (10 mol%), DBU (1 equiv), **1a** (1 equiv), Alkenyl-Br (1 equiv), DMF (0.35 M), 110 °C, 12 h. [b] Yield based on isolated product after flash chromatography. [c] Hermann-Beller catalyst used.



Scheme 2 Innovative access to fatty acid synthase inhibitors.

In the current context of intensive efforts in the discovery of therapeutics for the treatment of obesity-disorder, we directed the application towards an innovative synthesis of variously *N*-alkylated 2-aryl-4,4'-cyloalkylimidazolones claimed as fatty acid synthetase inhibitors (scheme 1).⁴ First, the *N*-isonicotinylimidazolone **1c** was successfully submitted to the optimized direct C-H arylation procedure to afford the imidazolone **3cK** in fair yield. Pleasingly, the subsequent methylation of **3cK** with iodomethane occurred only at the pyridine nitrogen. The pyridinium salt intermediate was subsequently cleanly reduced through the conventional double reduction with sodium borohydride and then dihydrogen under PtO₂ catalysis to provide the FAS inhibitor **6b** in 53% yield over two-step synthesis. Furthermore interestingly, we found that the isonicotinyl protection could be fully removed. Indeed, the PtO₂-catalyzed dihydrogen reduction of the pyridinium salt intermediate provided quantitatively the unprotected imidazolone **6a** previously used to prepare a wide variety of biologically active *N*-alkylated imidazolones.^{4,16}

Conclusions

As summary, we have developed an innovative and efficient synthetic methodology for direct C-H arylation and alkenylation of 4,4'-dialkylimidazolones under Pd⁽⁰⁾/Cu^(I) bis-catalysis. Several electronically-different aryl- and alkenyl halides proved to be efficient coupling partners enabling a wide range of 4,4'-dialkylimidazolones to be prepared in moderate to good yields. This novel methodology is functional group-tolerant, step-economical and highly flexible. This work represents one of first investigations in challenging direct C-H functionalization of non-aromatic heterocycles. Remarkably, the standard activation via *N*-oxidation is not required. This methodology may find direct applications in pharmacological and material sciences. As demonstration in this communication, an innovative and neat preparation of a recently-discovered *N*-alkylated 4,4'-cycloalkylimidazolone-based fatty acid synthase (FAS) inhibitor is proposed.

Acknowledgements

This work has been partially supported by INSA Rouen, Rouen University, CNRS EFRD, CRUNCH, Labex SynOrg (ANR-11-LABEX-0029).

Notes and references

^a Mickaël Muselli, Christine Baudequin, Christophe Hoarau, Laurent Bischoff

Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière 76821 Mont Saint Aignan Cedex, France

† Electronic Supplementary Information (ESI) available: [NMR spectra and data for all compounds]. See DOI: 10.1039/b000000x/

- (a) I. V. Yampolsky, A. A. Kislukhin, T. T. Amatov, D. Shcherbo, V. K. Potapov, S. Lukyanov, K. A. Lukyanov, *Bioorg. Chem.*, 2008, **36**, 96; (b) L. Wu, K. Burgess, *J. Am. Chem. Soc.*, 2008, **130**, 4089.
- (a) Y. Chen, S. J. O'Connor, D. Guan, J. Newcom, J. Chen, L. Yi, H. Zhang, L. M. Hunyadi, R. Natero, *WO PCT 058727*, 2004; (b) N. Murugesan, J. E. Tellew, J. E. Macor, Z. Gu, *WO PCT*, 01389, 2000;

- (c) N. Murugesan, J. E. Tellew, J. E. Macor, Z. Gu, *US PCT*, 0143024, 2002.
- 3 P. Ye, K. Sargent, E. Stewart, J.-F. Liu, D. Yohannes, L. Yu, *J. Org. Chem.*, 2006, **71**, 3137.
- 4 (a) M.S. Malamas, J. J. Erdei, W. F. Fobare, D. A. Quagliato, S. A. Antane, A. J. Robichaud, *US PCT*, 0072925, 2007; (b) S. Berg, J. Holenz, K. Hoegdin, J. Kihlstrom, K. Kolmodin, J. Lindstrom, N. Plobeck, D. Rotticci, F. Sehgelmeble, M. Wirstam, *WO PCT* 145569 A1, 2007; (c) S. Berg, J. Hallberg, K. Hoegdin, S. Karlstrom, A. Kers, N. Plobeck, L. Rakos, *WO PCT* 076044A1, 2008.
- 5 P. J. Connolly, T. L. Lu, M. H. Parker, D. Ludovici, C. Meyer, L. Meerpoel, K. Smans, C. Rocaboy, *WO PCT* 039769, 2014.
- 6 For recent reviews or significant examples, see: (a) M. S. Baranov, K. A. Lukyanov, I. Yampolsky, *Russ. J. Bioorg. Chem.*, 2013, **39**, 223; (b) P. E. Ivashkin, I. V. Yampolsky, K. A. Lukyanov, *Russ. J. Bioorg. Chem.*, 2009, **35**, 652; (c) C.-Y. Lee, Y.-C. Chen, H.-C. Lin, Y. Jhong, C.-W. Chang, C.-H. Tsai, C.-L. Kao, T.-C. Chien, *Tetrahedron*, 2012, **68**, 5898; (d) P. E. Ivashkin, K. A. Lukyanov, S. Lukyanov, I. V. Yampolsky, *J. Org. Chem.*, 2011, **76**, 2782; (e) R. Bossio, S. Marcaccini, P. Paoli, S. Papaleo, R. Pepino, C. Polo, *Liebigs Ann. Chem.*, 1991, 843.
- 7 (a) B. K. Rajbongshi, N. N. Nair, M. Nethaji, G. Ramanathan, *Cryst. Growth Des.*, 2012, **12**, 1823; (b) W.-T. Chuang, B.-S. Chen, K.-Y. Chen, C.-C. Hsieh, P.-T. Chou, *Chem. Commun.*, 2009, **45**, 6982; (c) G. Bhattacharjya, S. S. Agasti, G. Ramanathan, *Arkivoc*, 2006, **10**, 152; (d) M. Z. Badr, H. A. H. El-Sherief, M. E. Tadros, *Bull. Chem. Soc. Jpn.*, 1982, **55**, 2267.
- 8 (a) A. K. Mukerjee and P. Kumar, *Can. J. Chem.*, 1982, **60**, 317; (b) X. He, A.F. Bell, P.J. Tonge, *Org. Lett.* 2002, **4**, 1523
- 9 (a) S. Oumouch, M. Bourotte, M. Schmitt, J.-J. Bourguignon, *Synthesis* 2005, 25; (b) Gosling, S., Rollin, P., Tatibouet, A. *Synthesis* 2011, 3649.
- 10 For general reviews on direct C-H arylation of heterocycles, see: (a) R. Rossi, F. Bellina, M. Lessi, C. Manzini, *Adv. Synth. Catal.*, 2014, **356**, 17; (b) K. Hirano, M. Miura, *Synlett*, 2011, 294; (c) C. Liu, H. Zhang, W. Shi, A. Lei, *Chem. Rev.*, 2011, **111**, 1780; (d) J. Roger, A. L. Gottumukkala, H. Doucet *ChemCatChem*, 2010, **2**, 20; (e) F. Bellina, R. Rossi, *Adv. Synth. Catal.*, 2010, **352**, 1223; (f) F. Bellina, R. Rossi, *Tetrahedron* 2009, **65**, 10269; (g) D. Alberico, M. E. Scott, M. Lautens, *Chem. Rev.*, 2007, **107**, 174.
- 11 For general reviews on direct C-H alkenylation of heterocycles, see: (a) S. A. Girard, T. Knauber, C.-J. Li, *Angew. Chem. Int. Ed.*, 2014, **53**, 74; (b) S. I. Kozhushkov, L. Ackermann, *Chem. Sci.*, 2013, **4**, 886; (c) C. S. Yeung, V. M. Dong, *Chem. Rev.*, 2011, **111**, 1215; (d) S. H. Cho, J. Y. Kim, J. Kwak, S. Chang, *Chem. Soc. Rev.*, 2011, **40**, 5068; (e) S. Messaoudi, J.-D. Brion, M. Alami, *Eur. J. Org. Chem.*, 2010, 6495.
- 12 For examples of direct Pd-catalyzed C-H functionalization of non-aromatic heterocycles, see: (a) E. Demory, D. Farran, B. Baptiste, P. Y. Chavant, V. Blandin, *J. Org. Chem.*, 2012, **77**, 7901; (b) H. Zhao, R. Wang, P. Chen, B. T. Gregg, M. M. Hsia, W. Zhang, *Org. Lett.*, 2012, **14**, 1872; (c) L. Ackermann, S. Barfusser, C. Kornhaass, A. R. Kapdi, *Org. Lett.*, 2011, **13**, 3082; (d) N. Gigant, I. Gillaizeau, *Org. Lett.*, 2012, **14**, 3304.
- 13 (a) F. Bellina, S. Cauteruccio, R. Rossi, *Eur. J. Org. Chem.*, 2006, 1379; (b) F. Bellina, C. Calandri, S. Cauteruccio, R. Rossi, *Tetrahedron* 2007, **63**, 1970; (c) F. Bellina, S. Cauteruccio, R. Rossi *J. Org. Chem.*, 2007, **72**, 8543.
- 14 See supporting information for all details.
- 15 C. Verrier, C. Hoarau, F. Marsais *Org. Biomol. Chem.*, 2009, **7**, 647
16. The unprotected imidazolone **6a** could not be produced alternatively from **3aK** following standard protocols for removing the benzyl group from amide function.